COST-EFFECTIVENESS OF DENOSUMAB IN PREVENTING OSTEOPOROTIC FRACTURES IN POSTMENOPAUSAL WOMEN FROM THE PRIVATE HEALTH CARE SETTING PERSPECTIVE IN BRAZIL

被引：1

作者：

Barbosa, E. G. ^{[1
]}

Machado, M. ^{[1
]}

Araujo, G. T. B. D. ^{[2
]}

Etto, H. ^{[2
]}

Fonseca, M. ^{[3
]}

Olimpio, A. ^{[1
]}

机构：

[1] GlaxoSmithKline Ltda, Rio De Janeiro, Brazil

[2] Axia Bio, Sao Paulo, Brazil

[3] Fed Univ Sao Paulo Axia Bio Consulting, Sao Paulo, Brazil

来源：

VALUE IN HEALTH | 2012年 / 15卷 / 07期

关键词：

D O I：

10.1016/j.jval.2012.08.1396

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A446 / A447

页数：2

共 50 条

[1] Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women
Hiligsmann, Mickael
Boonen, Annelies
Dirksen, Carmen D.
Ben Sedrine, Wafa
Reginster, Jean-Yves
[J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (01) : 19 - 28
[2] Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women
Hiligsmann, Mickael
Reginster, Jean-Yves
[J]. BONE, 2010, 47 (01) : 34 - 40
[3] THE COST-EFFECTIVENESS OF DENOSUMAB FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES IN THE SETTING OF THE UNITED STATES
Jiang, Y.
Hay, J.
[J]. VALUE IN HEALTH, 2012, 15 (04) : A38 - A38
[4] COST-EFFECTIVENESS OF DENOSUMAB COMPARED WITH GENERIC ALENDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN
Hiligsmann, Mickael
Reginster, Jean-Yves
[J]. OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 112 - 113
[5] COST-EFFECTIVENESS OF DENOSUMAB COMPARED WITH GENERIC ALENDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN
Hiligsmann, M.
Reginster, J. Y.
[J]. VALUE IN HEALTH, 2010, 13 (07) : A309 - A310
[6] COST-EFFECTIVENESS OF DENOSUMAB COMPARED WITH ORAL BISPHOSPHONATES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN
Hiligsmann, M.
Reginster, J. Y.
[J]. OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 30 - 31
[7] Cost-effectiveness of raloxifene to prevent osteoporotic fractures among postmenopausal women in Australia
Lees, M
Graham-Clarke, P
Davey, P
Thiebaud, D
Grainger, D
[J]. OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S28 - S28
[8] The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women
Stevenson, M.
Davis, S.
Lloyd-Jones, M.
Beverley, C.
[J]. HEALTH TECHNOLOGY ASSESSMENT, 2007, 11 (04) : 1 - +
[9] A cost-effectiveness model of tibolone as treatment for the prevention of osteoporotic fractures in postmenopausal women in Sweden
Willis, M
Ödegaard, K
Persson, U
Hedbrant, J
Mellström, D
Hammar, M
[J]. CLINICAL DRUG INVESTIGATION, 2001, 21 (02) : 115 - 127
[10] A Cost-Effectiveness Model of Tibolone as Treatment for the Prevention of Osteoporotic Fractures in Postmenopausal Women in Sweden
Michael Willis
Knut Ödegaard
Ulf Persson
Johan Hedbrant
Dan Mellström
Mats Hammar
[J]. Clinical Drug Investigation, 2001, 21 : 115 - 127

← 1 2 3 4 5 →